Also known as: Plasma total homocysteine
Formal name: Homocysteine
Additional articles used in this review
- Verhoef P and others. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 17:989-995, 1997.
- Ridker PM and others. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281:1817-1821, 1999.
- Loralie J and others. Hyperhomocyst(e)inemia and the increased Rrisk of venous thromboembolism. Archives of Internal Medicine 160:961-964, 2000.
- Tanne D and others. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 34:632-636, 2003.
- Kang SS and others. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annual Review of Nutrition 12:279-298, 1992.Rimm EB and others. Folate and Vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 279:359-364, 1998.
- Malinow MR and others. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 99:178-182, 1999.
- Eikelboom JW and others. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Annals of Internal Medicine 131:363-375, 1999.
- Hackam DG and others. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. American Journal of Hypertension 13:105-100, 2000.
- Schnyder G and others. Homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: A randomized controlled trial. JAMA 288:973-979, 2002.
- Toole JF and others. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565-575, 2004.
- Bønaa KH and others. Homocysteine lowering and cardiovascular events after acute myocardial infarction. New England Journal of Medicine 354:1578-1588, 2006.
- Albert CM and others. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299:2027-2036, 2008
- Ebbing M and others. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 300:795-804, 2008.
- SEARCH Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardialinfarction survivors: A randomized trial. JAMA 303:2486-2494, 2010.
- House AA and others. Effect of B-vitamin on progression of diabetic nephropathy: A controlled trial. JAMA 303:603-1309, 2010.
- Lonn E. Homocysteine-lowering B vitamin therapy in cardiovascular prevention—Wrong again? JAMA 299:2086-2087, 2008.